Raphael J. Landovitz, MD
Assistant Professor
University of California Los Angeles
Los Angeles, California

Research Topics

• Biomedical prevention of HIV
• HIV drug resistance: clinical and mechanistic correlates
• Prevention of mother-to-child transmission of HIV
  
  
  

Lecture and Writing Topics

• HIV prevention
• Mechanisms of resistance (including new agents)
• Prevention of mother-to-child transmission of HIV
  
  
  

Current Professional Summary

Dr Landovitz is an Assistant Professor at University California Los Angeles (UCLA) and is with the UCLA Center of Clinical AIDS Research and Education. He is also the Intervention Core Co-Director at UCLA Center for HIV Identification, Prevention, and Testing (CHIPTS) and is a member of the American Academy of HIV Medicine Research Task Force.


Committees and Organizations

• Member, Infectious Diseases Society of America
• Member, American Academy of HIV Medicine
• Member, Massachusetts Medical Society
  
  

Honors and Awards

• Edward H. Kaas Award for Clinical Excellence in Infectious Diseases, Massachusetts Infectious Diseases Society
• Undergraduate Medical Education Training Award, Harvard Medical School, Boston, Massachusetts
• Society of Teaching Fellows, Harvard Medical School, Boston, Massachusetts
  
  

Education

• Princeton University, BA Summa cum laude (1992)
• Harvard Medical School, MD (1996)
• University of California Los Angeles, MSc (projected 2009)
  
  
  

Selected Publications

1. Landovitz RJ, Sax PE. Symptomatic junctional bradycardia after treatment with nelfinavir. Clin Infect Dis. 1999;29:449-450.
2. Landovitz RJ, Sax PE. NRTI-associated mitochondrial toxicity. AIDS Clin Care. 2001;13:43-52.
3. Landovitz RJ, Winkelman JW, Yawetz S, Koziol C, Sax PE. Efavirenz increases slow-wave sleep. [Abstract 715.] 10th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002; Boston, MA.
4. Landovitz RJ, Jaganathan P, Bhatt A et al. Preventing HIV Infection after a potential sexual exposure. Infect Med. 2007;24: 236-246.
5. Jaganathan P, Landovitz RJ, Roland, M. Post-Exposure Prophylaxis after Sexual Exposure to Human Immunodeficiency Virus. Future HIV Therapy. 1: 35-47.
6. Rotheram-Fuller E, De La Garza R 2nd, Mahoney JJ 3rd, Shoptaw S, Newton TF. Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. Psychiatry Res. 2007;152:205-210.
7. Daskalakis DC, Landovitz RJ, Cespedes, M. Sexual Health in Makadon HJ, Mayer KH, Potter J, et al. Eds. Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health, ACP Press, Philadelphia, 2008.
8. Landovitz RJ. Recent Efforts in Biomedical Prevention of HIV. Top HIV Med. 2007;15:99-103.
9. Roland ME, Neilands TB, Krone MR, et al. Telephone hotline provides human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) initiation and referrals following sexual exposures. Clin Infect Dis. 2007; in preparation.
10. Landovitz RJ, Angel JB, Hoffmann C, et al. Results of a dose-finding study of the CCR5 antagonist vicriviroc plus zidovudine/lamivudine in HIV-infected treatment-naïve subjects. J Infect Dis. 2007, submitted.